We are channeling nearly three decades of scientific insights and expertise to discover and develop the next generation of cancer therapies. Our commitment to innovation is fueled by a sense of urgency to turn learnings into meaningful advances for patients.
Inspired by science
Our cross-functional team is hard at work looking at oncology innovation from every angle. Using our experience across a wide spectrum of technologies and scientific approaches in oncology drug discovery and development, we innovate with both biotherapeutics and small molecules, allowing us to tailor our approach to best suit the target biology and the patient.
Pipeline expansion is a key driver of our growth strategy. We continue to make significant progress across our internal discovery projects and collaborations to generate biotherapeutics, including antibody-drug conjugates, and small molecules – with the goal of pursuing medical advances across a wide number of tumor types.
Our portfolio of clinically differentiated compounds is being evaluated in the lab and in clinical trials for their potential to treat a broad array of tumors.
Creating transformational treatments
We have built industry-leading expertise across all aspects of drug discovery, design and optimization. These core capabilities have evolved and advanced over the years, resulting in the advancement of a broad array of diverse biotherapeutics and small molecule programs for the treatment of cancer exploring multiple modalities and mechanisms of action.
We have extensive expertise in the clinical development of oncology products, which we continue to leverage to advance our next generation of cancer treatments: innovative therapies that have the potential to help cancer patients recover stronger and live longer.
Our development efforts begin by taking optimized drug candidates into investigational first-in-human clinical studies. We work closely with our partners, clinicians and health authorities to design and conduct clinical trials that assess safety, determine proper dosing and demonstrate the therapeutic potential of our compounds alone or in novel combination regimens.
Strategic partnerships maximize the value of our approved treatments and support our investigation of experimental molecules alone and in combination with other therapeutic agents. By partnering with organizations that share our commitment to advancing cancer treatments, we can deliver more medicines to more patients around the world.
Inspired by science, compelled by data
Seeing how difficult it was for patients undergoing chemotherapy at the start of my profession motivated me to pursue the career I have in drug development today. Knowing my team’s efforts with novel approaches to cancer therapies may give people more time with their loved ones is what gets me going every morning and fuels my passion and strong sense of purpose for helping patients live longer.